Unicycive Therapeutics (NASDAQ:UNCY) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCYFree Report) in a research note published on Monday, Benzinga reports. They currently have a $4.50 price target on the stock.

UNCY has been the subject of several other research reports. Benchmark reaffirmed a speculative buy rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research report on Monday, December 4th. Noble Financial assumed coverage on shares of Unicycive Therapeutics in a research report on Wednesday, February 14th. They issued an outperform rating and a $6.00 price target for the company.

Get Our Latest Analysis on UNCY

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $1.41 on Monday. The stock has a market cap of $49.00 million, a price-to-earnings ratio of -0.91 and a beta of 2.66. Unicycive Therapeutics has a 1 year low of $0.47 and a 1 year high of $2.29. The firm has a 50-day moving average of $1.31 and a two-hundred day moving average of $0.91.

Unicycive Therapeutics (NASDAQ:UNCYGet Free Report) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. Research analysts expect that Unicycive Therapeutics will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. RA Capital Management L.P. bought a new position in shares of Unicycive Therapeutics during the 3rd quarter worth approximately $2,985,000. Vivo Capital LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter valued at approximately $2,984,000. Balyasny Asset Management L.P. acquired a new position in Unicycive Therapeutics during the 1st quarter valued at approximately $1,506,000. Goldman Sachs Group Inc. acquired a new position in Unicycive Therapeutics during the 2nd quarter valued at approximately $123,000. Finally, Geode Capital Management LLC increased its stake in Unicycive Therapeutics by 267.3% during the 1st quarter. Geode Capital Management LLC now owns 95,898 shares of the company’s stock valued at $201,000 after purchasing an additional 69,789 shares in the last quarter. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Further Reading

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.